Shares of Medgenics Inc (NASDAQ:GNMX) have earned an average broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating. Medgenics’ rating score has declined by 20% from three months ago as a result of a number of analysts’ upgrades and downgrades.

Brokers have set a one year consensus price target of $5.00 for the company and are predicting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also given Medgenics an industry rank of 241 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

A hedge fund recently raised its stake in Medgenics stock. Renaissance Technologies LLC boosted its position in Medgenics Inc (NASDAQ:GNMX) by 515.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 93,600 shares of the biotechnology company’s stock after purchasing an additional 78,400 shares during the quarter. Renaissance Technologies LLC owned about 0.16% of Medgenics worth $112,000 as of its most recent filing with the Securities and Exchange Commission. 20.44% of the stock is currently owned by institutional investors.

Medgenics stock opened at $1.55 on Tuesday. Medgenics has a 52 week low of $0.98 and a 52 week high of $2.65. The stock has a market capitalization of $105.62, a P/E ratio of -1.87 and a beta of 1.03.

Medgenics (NASDAQ:GNMX) last announced its earnings results on Tuesday, March 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. analysts anticipate that Medgenics will post -0.63 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at

About Medgenics

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn's disease.

Get a free copy of the Zacks research report on Medgenics (GNMX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with's FREE daily email newsletter.